CoChat

Recombinant human interleukin‐1 receptor type I in the treatment of patients with active rheumatoid arthritis

Drevlow, Barbara E., Lovis, Rosa, Haag, Mary Ann, Sinacore, James M., Jacobs, Cindy, Blosche, Consuelo, Landay, Alan, Moreland, Larry W., Pope, Richard M. · 1996 · Arthritis & Rheumatism
Cited by 103

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Objective. To determine the safety and efficacy of recombinant soluble human interleukin‐1 receptor type I (rHuIL‐1RI) administered subcutaneously in patients with active rheumatoid arthritis (RA). Methods. Twenty‐three patients with active RA (>5 swollen joints) were enrolled into a randomized, double‐blind, 2‐center study. Patients received subcutaneous doses of rHuIL‐1RI or placebo for 28 consecutive days. Patients were treated with 125, 250, 500, or 1,000 μg/m 2/day of rHuIL‐1RI. Physical examinations and laboratory assessments were performed at baseline (day 1), and 8, 15, 22, 29, 43, and 57 days after the start of the study. Analysis of peripheral blood by flow cytometry was performed on days 1 and 29 to determine the effects of rHuIL‐1RI on the distribution and phenotypic characteristics of circulating inflammatory cells. Results. Four of 8 patients who received rHuIL‐1RI at 1,000 μg/m 2/day demonstrated improvement in at least 1 of 8 individual measures of disease activity; however, only 1 of these 4 patients experienced clinically relevant improvement as defined by predetermined criteria. None of the patients treated with smaller doses of rHuIL‐1RI, and none of the placebo‐treated control patients, experienced any improvement as defined by the predetermined criteria. Monocyte cell surface IL‐1α was significantly reduced following treatemnt with rHuIL‐1RI at each dosage. Administration of rHuIL‐1RI was stopped prematurely because of dose‐limiting rashes in 2 pateints treated with 1,000 μg/m 2/day. No other adverse events prevented completion of the study. Conclusion. Only 1 patient, who was treated with the highest concentration of rHuIL‐1RI employed (1,000 μg/m 2/day), demostrated clinically relevant improvement in this phase I study on this small group of patients with active RA. Dose‐limiting toxicity was also observed in 2 pateints treated with this highest concentration of rHuIL‐1RI. Treatment with rHuIL‐1RI did result in a reduction of monocyte cell surface IL‐1α, which indicates that the dosages of rHuIL‐1RI employed were functional.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.1780390212

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 103

Metadata

Authors
Drevlow, B. E., Lovis, R., Haag, M. A., Sinacore, J. M., Jacobs, C., Blosche, C., Landay, A., Moreland, L. W., & Pope, R. M.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
1996-02
Volume
39
Issue
2
Pages
257-265
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W1974603163
Cited by
103
References
2
FWCI
10.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.